Group characteristics (continuous variables) at baseline (A) and 2-year follow-up (B).

Abb. UPDRS-III: Unified Parkinson’s Disease Rating Scale, motor section; MMSE: Mini Mental State Examination; FAB: Frontal Assessment battery; HADS: Hospital Anxiety Depression Scale; HADS-D: Hospital Anxiety Depression Scale-depression subscale; HADS-A: Hospital Anxiety Depression Scale-anxiety subscale; NMS: non-motor symptoms; NMS-D: non-motor domains; LEDD: Levo-dopa equivalent daily dosage.adifferent from group 4 (pbdifferent from group 1 (pcdifferent from all groups (pddifferent from group 2 and 4 (pedifferent from group 2 (pfdifferent from group 1 and 3 (pgdifferent from group 1 and 2 (p

图 统一帕金森病评定量表第三部分（Unified Parkinson’s Disease Rating Scale-III, UPDRS-III）：运动分项量表；简易精神状态检查（Mini Mental State Examination, MMSE）；额叶评估量表（Frontal Assessment Battery, FAB）；医院焦虑抑郁量表（Hospital Anxiety Depression Scale, HADS）；医院焦虑抑郁量表抑郁亚分量表（Hospital Anxiety Depression Scale-depression subscale, HADS-D）；医院焦虑抑郁量表焦虑亚分量表（Hospital Anxiety Depression Scale-anxiety subscale, HADS-A）；非运动症状（non-motor symptoms, NMS）；非运动维度（non-motor domains, NMS-D）；左旋多巴等效日剂量（Levo-dopa equivalent daily dosage, LEDD）。a 与第4组存在差异（p）；b 与第1组存在差异（p）；c 与所有组别均存在差异（p）；d 与第2组和第4组存在差异（p）；e 与第2组存在差异（p）；f 与第1组和第3组存在差异（p）；g 与第1组和第2组存在差异（p）